MicroTech Medical (Hangzhou) Co

MicroTech Medical (Hangzhou) Co R&D per Employee

The R&D Spending per Employee of MicroTech Medical (Hangzhou) Co (2235.HK) as of Nov 3, 2026 is 134,875.27 CNY. In the previous year, R&D Spending per Employee was 116,172.99 CNY — a change of 16.10% (higher).

R&D per Employee

134,875.27CNY

YoY

16.10%

Last updated:

R&D Spending per Employee of MicroTech Medical (Hangzhou) Co is 2025 134,875.27 CNY. R&D Spending per Employee of MicroTech Medical (Hangzhou) Co was 2024 116,172.99 CNY. It decreases by 16.10% higher compared to the previous year.

The MicroTech Medical (Hangzhou) Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
88,446.54 CNY
Jan 1, 2020
144,894.37 CNY
Jan 1, 2021
26,182.37 CNY
Jan 1, 2022
54,057.34 CNY
Jan 1, 2023
106,370.88 CNY
Jan 1, 2024
116,172.99 CNY
Jan 1, 2025
134,875.27 CNY
The MicroTech Medical (Hangzhou) Co R&D per Employee history
YEARR&D per EmployeeYoY
134,875.27CNY+16.10%
116,172.99CNY+9.22%
106,370.88CNY+96.77%
54,057.34CNY+106.46%
26,182.37CNY-81.93%
144,894.37CNY+63.82%
88,446.54CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MicroTech Medical (Hangzhou) Co Stock analysis

What does MicroTech Medical (Hangzhou) Co do? MicroTech Medical (Hangzhou) Co., Ltd. generates revenue through the sale of diabetes management medical devices and consumables, including the Equil applicator insulin pump system, blood glucose monitoring systems, and the AiDEX G7 continuous blood glucose monitoring system. These products are commercialized for overseas markets such as the United States and the European Union, targeting healthcare providers and patients seeking advanced diabetes care solutions. The company's R&D efforts focus on developing products like the artificial pancreas, which remains in the research phase but is expected to contribute to future revenue streams. The firm's primary customers are healthcare institutions and end-users in international markets, with a strong emphasis on the United States and European Union regions. By leveraging its established product portfolio, MicroTech Medical capitalizes on the growing demand for innovative diabetes management solutions, ensuring consistent revenue from both existing and emerging product lines. The company's IPO in 2021 provided additional capital to support further development and market expansion. MicroTech Medical (Hangzhou) Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MicroTech Medical (Hangzhou) Co stock

R&D Spending per Employee of MicroTech Medical (Hangzhou) Co is 134,875.27 CNY in 2025.

R&D Spending per Employee of MicroTech Medical (Hangzhou) Co changed from 116,172.99 CNY to 134,875.27 CNY, representing a 16.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee MicroTech Medical (Hangzhou) Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's MicroTech Medical (Hangzhou) Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — MicroTech Medical (Hangzhou) Co

All Key Metrics — MicroTech Medical (Hangzhou) Co